Some NAM patients have autoantibodies (aAbs) against the statins drug target, that is 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR). This evidence concerns the gene HMGCR and Bailey-Bloch congenital myopathy.